While the physiological relevant EV dose and treatment duration remainns to be defined, the current findings suggest that uptake of EVs by recipient cells in a microenvironment and at distal sites under pathological conditions, such as cancer, could result in immediate and systemic NFkB responses, respectively. This evidence concerns the gene NFKB1 and cancer.